TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/19/2025
Back to search
Official data from USPTO
GLENMARK THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
GLENMARK THERAPEUTICS
ST13
US500000097976501Class
5
Filing
97976501
Registration
7317749
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
05/24/2025
Trademark type
Word
Nice classes
5
Filing date
04/04/2022
Registration date
02/27/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/27/2024
Last transaction
05/24/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
07/06/2022
First use in commerce
08/01/2022
Drawing code
4
Owner type
03
Owner location
Mahwah, NJ
Examiner
AGOSTO, GISELLE
Law office
L20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Glenmark Therapeutics Inc., USA
Representatives
Maxim A. Voltchenko KAPLAN BREYER SCHWARZ, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationscontraceptive preparations; pharmaceutical preparationsantacidsacid reducers for the management of heartburn
Publications
History of USPTO decisions and trademark events.
41 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/19/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/19/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/19/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/19/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/27/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
02/27/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/25/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/24/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/15/2023
GNRT
NON-FINAL ACTION E-MAILED
12/15/2023
CNRT
SU - NON-FINAL ACTION - WRITTEN
12/15/2023
DPCC
DIVISIONAL PROCESSING COMPLETE
09/18/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/31/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/26/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/04/2023
DRRR
DIVISIONAL REQUEST RECEIVED
05/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/03/2023
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
05/03/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/27/2023
GNRT
NON-FINAL ACTION E-MAILED
03/27/2023
CNRT
SU - NON-FINAL ACTION - WRITTEN
03/27/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/16/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
02/16/2023
IUAF
USE AMENDMENT FILED
01/18/2023
EISU
TEAS STATEMENT OF USE RECEIVED
01/18/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/15/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/20/2022
PUBO
PUBLISHED FOR OPPOSITION
09/20/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/31/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/17/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/22/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/22/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/22/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/12/2022
GNRT
NON-FINAL ACTION E-MAILED
05/12/2022
CNRT
NON-FINAL ACTION WRITTEN
05/12/2022
DOCK
ASSIGNED TO EXAMINER
05/11/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/08/2022
NWAP
NEW APPLICATION ENTERED
04/07/2022
Continuous trademark protection
Get notified about every new filing that threatens GLENMARK THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.